Research | Home

Molecular and functional characterization of small molecular inhibitor to evaluate antitumor activity in acute myeloid leukemia

The project is focused on the elucidation of alterations in signaling pathways leading to survival advantage and resistance to apoptosis in leukemic blast and develops innovative therapeutic approaches, with a focus on CDK7 inhibition and modulating redox homeostasis. Further, using in vitro, ex vivo and in vivo models of AML, we seeks to identify critical targets associated with Venetoclax/Cytarabine resistance and incorporate the novel targets in treatment regime to overcome the resistance.

High-risk acute promyelocytic leukemia and novel therapeutics

The project on high-risk Acute Promyelocytic Leukemia (APL) is a comprehensive research endeavor that combines proteomics and genomics to gain a deeper understanding of acquired arsenic trioxide (ATO) resistance. With the use of different APL models together with novel therapeutic combinations, we aim to overcome ATO resistance.

Harnessing the power of single-cell multiomics to uncover the complexities of acute promyelocytic leukemia

By leveraging the use of biological materials from acute promyelocytic leukemia (APL) patients and transgenic PML-RARA murine models, we aim to study the molecular mechanisms underlying coagulopathy in APL

Leveraging functional genomics and single cell profiling to delineate genetic trajectories of therapy resistance in acute myeloid leukemia

Acute myeloid leukemia (AML) is the deadliest of all blood cancers, killing around 75-80% of patients within five years. Our laboratory is exploiting cutting-edge high throughput techniques like CRISPR-Cas9 based screening in AML cell lines supplemented with single cell multi-omics in ex-vivo AML patient samples to decipher the intricacies of therapy resistance in AML. We also employ BH3 profiling to scrutinize altered apoptotic dependencies in in vivo and ex vivo model systems. We are focused at delving deeper into the multiverse of AML biology and to probe unexplored therapeutic targets to bring to light novel therapeutic molecules for improvement of disease outcomes.

Deciphering the tumor-associated functions of Pregnancy Zone Protein in Breast Cancer

Pregnancy Zone Protein (PZP), a proteinase inhibitor, has been implicated in etiology of various cancers. Through this study, we aim to identify and characterize novel interacting partners of PZP along with exploration of the TGFβ/SMAD pathway, TGFβ being a known interacting partner of PZP. Additionally, we aim to understand the role of PZP in cancer progression and metastasis using orthotopic xenograft murine models.